Drug Trial Radar · NCT00955526
Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Last checked: Nov 20, 2026Latest source record: Aug 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
373
Actual
Start
Jul 2009
Primary completion
Feb 2011
Study completion Feb 2011
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa. Patients who meet entry criteria will be randomized in a 1:1:1 ratio to double blind treatment with oral doses of 20 or 40 mg/day istradefylline or matching placebo. Patients will be treated for 12 weeks and will have interim visits and end of treatment visit to assess the efficacy and safety of istradefylline.
Conditions
- Parkinson's Disease
Interventions
IstradefyllineDrug
20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
IstradefyllineDrug
40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
PlaceboDrug
Two placebo tablets once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reducing the mean total hours of awake time per day spent in the OFF state
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.